DDIS-12. ONC201: THE FIRST SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY

ONC201 has exhibited preliminary clinical evidence of anti-tumor activity and safety in high grade glioma patients. In this study, we identified and characterized a previously unknown binding target of ONC201. BANDIT – a machine learning-based target identification platform – predicted that ONC201 w...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Vijay Prabhu, Varun, Madhukar, Neel, Anantharaman, Lakshmi, Sulli, Chidananda, Davidson, Edgar, Deacon, Sean, Tarapore, Rohinton, Rucker, Joseph, Charter, Neil, Doranz, Benjamin, Oster, Wolfgang, Stogniew, Martin, Elemento, Olivier, Free, R Benjamin, Sibley, David, Allen, Joshua
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216563/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.291
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items